Status:
TERMINATED
Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Mood
Memory Deficit
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The primary purpose is to determine if patients scheduled to receive prescription corticosteroid therapy for inflammatory illnesses who are given either memantine or riluzole pretreatment will show le...
Detailed Description
Twenty five (25) outpatients with pulmonary (e.g. asthma, cystic fibrosis) or rheumatic (e.g. rheumatoid arthritis, dermatomyositis) illnesses scheduled to receive a brief course ("burst") of predniso...
Eligibility Criteria
Inclusion
- 18-70 years old
- English speaking
- Able to provide informed consent
- Scheduled to receive a corticosteroid burst of at least 20 mg prednisone or equivalent for at least 7 days
Exclusion
- History of allergic reaction to memantine and/or riluzole
- Pregnant or nursing women
- History of liver disease, myocardial infarction, renal failure, diabetes with poor glycemic control, or other unstable medical condition
- Mental retardation, dementia, or other severe cognitive disorder
- Prior prednisone therapy in the last 14 days
- Current alcohol/substance abuse/dependence
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00283309
Start Date
November 1 2005
End Date
April 1 2007
Last Update
April 23 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern
Dallas, Texas, United States, 75390